Can a pill replace EPO shots for anemia in kidney disease?

NCT ID NCT02075463

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing an experimental oral drug, GSK1278863, in people on dialysis who have anemia due to chronic kidney disease and who don't respond well to standard erythropoietin (EPO) injections. The goal is to see if the drug can raise or maintain hemoglobin levels within a target range over 16 weeks. Participants will switch from EPO to the study drug, and the study will monitor safety and effectiveness. This is a small, early-stage study that will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK1278863, an experimental oral drug being tested as an alternative to standard erythropoietin injections for anemia in kidney disease
What this could lead to: If successful, this could offer a new oral option for dialysis patients with anemia who don't respond well to current treatments, potentially improving their blood counts and reducing the need for injections.
What could go wrong: This is a small, early-stage trial with only 15 participants, so results may not apply broadly. The drug may not work as hoped or could have side effects, and more research will be needed before it becomes available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAEMIA ANEMIA

Contacts and locations

Locations

GSK Investigational Site

Azusa, California, 91702, United States
GSK Investigational Site

Glendale, California, 91204, United States
GSK Investigational Site

Los Angeles, California, 90025, United States
GSK Investigational Site

Simi Valley, California, 93065, United States
GSK Investigational Site

Hollywood, Florida, 33024, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

Amherst, New York, 14226, United States
GSK Investigational Site

Bethlehem, Pennsylvania, 18017, United States
GSK Investigational Site

Knoxville, Tennessee, 37923, United States
GSK Investigational Site

Houston, Texas, 77004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.